Home › Activist investors › Caligan Partners
Campaign activist. Positions and campaigns from Caligan Partners’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
| Company | Stake | Source | First disclosed | Last change | Since previous filing | Flags | Stated intent |
|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. | 9.70%8,736,898 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | May 15, 2026 | Increased Nov 16, 2026 | ▲ 0.94 pts | Increased | 13F: none stated |
| Sagimet Biosciences Inc. | 8.58%2,794,484 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 | Aug 14, 2026 | Increased Nov 16, 2026 | ▲ 0.90 pts | Increased | 13F: none stated |
| Avalo Therapeutics, Inc. | 5.65%3,268,303 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Nov 14, 2025 | Increased Nov 16, 2026 | ▼ 0.25 pts | Increased | 13F: none stated |
| LB Pharmaceuticals Inc | 4.66%1,509,621 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 | May 15, 2026 | Increased Nov 16, 2026 | ▲ 0.21 pts | Increased | 13F: none stated |
| Aura Biosciences, Inc. | 4.43%4,590,253 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 6, 2026 | Aug 14, 2025 | Increased Nov 16, 2026 | ▲ 0.28 pts | Increased | 13F: none stated |
| Sensei Biotherapeutics, Inc. | 3.44%890,210 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | May 15, 2026 | Increased Nov 16, 2026 | ▲ 1.01 pts | Increased | 13F: none stated |
| Immunocore Holdings Plc | 3.24%1,672,141 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 | Aug 14, 2026 | Increased Nov 16, 2026 | ▲ 0.55 pts | Increased | 13F: none stated |
| Artiva Biotherapeutics, Inc. | 3.03%1,481,043 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 | Aug 14, 2026 | Decreased Nov 16, 2026 | ▼ 0.52 pts | Decreased | 13F: none stated |
| ADMA Biologics, Inc. | 2.65%5,875,007 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | May 15, 2023 | Increased Nov 16, 2026 | ▲ 0.09 pts | Increased | 13F: none stated |
| Tyra Biosciences, Inc. | 1.53%910,749 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 | May 15, 2025 | Increased Nov 16, 2026 | ▲ 0.17 pts | Increased | 13F: none stated |
| Verrica Pharmaceuticals Inc. | 10.0%6,503,054 shares | Schedule 13D/A, filed Dec 30, 2025 | Nov 24, 2025 | — | 0.00 pts | — | Standard Item 4 language |
| Anika Therapeutics, Inc. | 9.9%1,435,130 shares | Schedule 13D/A, filed Jan 27, 2026 | Aug 17, 2023 | — | 0.00 pts | — | Seeks changes or engagement |
| Opus Genetics, Inc. | 7.16%5,960,972 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 3, 2026 | May 15, 2026 | — | ▼ 0.14 pts | — | 13F: none stated |
| Cellectar Biosciences Inc. | 4.97%469,998 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 11, 2026 | Aug 14, 2026 | — | 0.00 pts | — | 13F: none stated |
| Vor Biopharma Inc. | 3.13%1,925,066 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 | Feb 17, 2026 | — | ▼ 0.12 pts | — | 13F: none stated |
| Viridian Therapeutics, Inc. | 1.93%2,193,981 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Aug 14, 2026 | — | 0.00 pts | — | 13F: none stated |
| Tango Therapeutics, Inc. | 1.48%2,501,246 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 4, 2026 | Feb 17, 2026 | — | 0.00 pts | — | 13F: none stated |
| Vaxcyte, Inc. | 1.38%2,188,636 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Feb 17, 2026 | — | ▼ 0.09 pts | — | 13F: none stated |
| Exelixis, Inc. | — | Schedule 13D/A, filed Jun 2, 2023stake not read from this filing’s format: see the filing | Jun 2, 2023 | — | — | — | Standard Item 4 language |
| Liquidia Corp | — | Schedule 13D/A, filed Sep 12, 2024stake not read from this filing’s format: see the filing | Dec 14, 2023 | — | — | — | Standard Item 4 language |
Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.
Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.
“On December 26, 2025, pursuant to the Purchase Agreement, the Issuer appointed Dr. Charles Frantzreb, a designee selected by Caligan, as a Class I member of the Board, effective immediately.”
“Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: On May 28, 2024, the Reporting Persons and certain of their affiliates entered into a Cooperation Agreement with the Issuer (the “ Cooperation Agreement ”). Pursuant to the Cooperation Agreement, Caligan withdrew its prior nomination of individuals to the Board of Directors (the “ Board ”) of the Issuer and the Issuer appointed William Jellison (one of the individuals Caligan nominated…”
Item 4 in the Schedule 13D/A filed Jan 27, 2026; this amendment did not restate Item 4, so the text is from the filing of May 30, 2024.
“Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: On May 31, 2023, Mr. Johnson was elected to the board of directors of the Issuer at the 2023 Annual Meeting. As a result, the Nomination Agreement terminated in accordance with its terms.”
“Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: On September 10, 2024, certain Caligan Funds entered into a Common Stock Purchase Agreement (the “ 2024 Purchase Agreement ”) with the Issuer for the purchase from the Issuer in a private placement (the “ 2024 Private Placement” ) of an aggregate of 1,123,595 shares (the “ 2024 Private Placement Shares”
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Anika Therapeutics, Inc.Board seats | Settled (agreement with the company) | May 28, 2024 | Feb 21, 2023 | Proxy contest filed (preliminary proxy) | latest (9) | — |
| Amag Pharmaceuticals, Inc.Board seats | No campaign filings in the last 12 months | Sep 26, 2019 | Sep 4, 2019 | Proxy contest filed | latest (6) | — |
| Knowles CorpBoard seats | No campaign filings in the last 12 months | Apr 18, 2019 | Mar 29, 2019 | Proxy contest filed | latest (6) | — |
| Company | Last stake | Source | Outcome | Date |
|---|---|---|---|---|
| Alimera Sciences Inc | — | Schedule 13D/A, filed Sep 18, 2024stake not read from this filing’s format: see the filing | Reported below 5% in a 13D/A | Sep 18, 2024 |
| Standard Biotools Inc. | — | Schedule 13D/A, filed Jan 8, 2024stake not read from this filing’s format: see the filing | Not in the 13F for the quarter ended Mar 31, 2024 | May 13, 2024 |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
No proxy contest has gone to a vote since July 1, 2023.
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Anika Therapeutics, Inc. | Settlement | agreement with the company | May 30, 2024 | Feb 21, 2023 |
| Amag Pharmaceuticals, Inc. | No outcome in the filings read | — | Sep 26, 2019 | Sep 4, 2019 |
| Knowles Corp | No outcome in the filings read | — | Apr 18, 2019 | Mar 29, 2019 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 1 of 6 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
| Company | First 13D | To latest close | SPY same dates | 6 months after | 12 months after |
|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. VRCA | Nov 24, 2025 | -39.5%Nov 24, 2025 – Nov 18, 2026 | +9.2% | +27.5%SPY +12.2% | not yet / no price |
Prices: daily closes (Nasdaq), as stored by the site.
Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.
“Pursuant to the Cooperation Agreement, Caligan withdrew its prior nomination of individuals to the Board of Directors (the “ Board ”) of the Issuer and the Issuer appointed William Jellison (one of the individuals Caligan nominated) and Joseph Capper to the Board effective as of May 28, 2024.” 13D Item 4, May 30, 2024
“Following the recommendation of a candidate for Replacement Designee by the Nominating Committee, the Board shall promptly appoint such Replacement Designee to the Board, subject to a Fiduciary Duty Determination.” 8-K, May 28, 2024
“In connection with the execution and delivery of this Agreement, on the date hereof, the Board shall increase the size of the Board to ten directors and appoint (i) William Jellison (the “ Investor Group Designee ”) as a Class I director to the Board and (ii) Joseph Capper as a Class II director to the Board to fill the vacancies resulting from the increase in the size of the Board.” 8-K, May 28, 2024
“…t to any publicly available information, including information in documents filed with the SEC), would result in such Third Party, together with its Affiliates and Associates, owning, controlling or otherwise having any beneficial or other ownership interest in the aggregate of more than 4.9% of the shares of Common Stock outstanding at such time or would increase the beneficial ownership interest of any Third Party who, together with its Affiliates and Associates, has a bene…” 8-K, May 28, 2024
“The Company agrees that concurrently with his appointment to the Board, each of Mr. Capper and the Investor Group Designee shall be appointed to the Capital Allocation Committee of the Board and, during the Standstill Period, the Company agrees to maintain the size of the Capital Allocation Committee at five (5) directors, subject to a Fiduciary Duty Determination.” 8-K, May 28, 2024
“RECITALS WHEREAS, certain members of the Investor Group submitted a letter to the Company on March 6, 2024 (the “ Nomination Notice ”) nominating two director candidates to be elected to the Board of Directors of the Company (the “ Board ”) at the Company’s 2024 Annual Meeting of Stockholders (the “ 2024 Annual Meeting ”); and WHEREAS, the Company and the Investor Group have determined to come to an agreement with respect to the matters set forth in this Agreement.” 8-K, May 28, 2024
“(b) Notwithstanding anything to the contrary contained in this Agreement, Section 2(b) , this Section 10 , and Section 12 through Section 16 shall not terminate at the end of the Standstill Period, but shall remain in full force and effect through the conclusion of the 2025 Annual Meeting.” 8-K, May 28, 2024
“Voting Commitments . 4 (a) During the Standstill Period, each of the members of the Investor Group shall appear in person or by proxy at each Stockholder Meeting for quorum purposes and to vote all shares of Common Stock beneficially owned by it and over which it has voting power in accordance with the Board’s recommendations as such recommendations of the Board are set forth in the applicable definitive proxy or consent statement filed in respect thereof with respect to: (i)…” 8-K, May 28, 2024
“During the Standstill Period, the Investor Group has also agreed to certain standstill provisions, including, among other things, agreeing not to, subject to certain exceptions, (i) acquire cumulative ownership (directly or indirectly) of more than 7.5% of the Company’s outstanding common stock, (ii) transfer its shares of common stock to any third party that would result in such third party owning more than 4.9% of the Company’s outstanding common stock, (iii) nominate or re…” 8-K, Apr 13, 2023
“Mr. Fischetti will also be appointed to the Compensation Committee of the Board.” 8-K, Apr 13, 2023
“…tions for election to the Board at the Company’s 2024 annual meeting of stockholders (such period, the “Standstill Period”), the Investor Group has agreed to appear in person or by proxy at each meeting of the Company’s stockholders and to vote all of its shares of the Company’s common stock in accordance with the Board’s recommendation with respect to the election, removal and/or replacement of directors and any other proposal that is submitted to the stockholders of the Com…” 8-K, Apr 13, 2023
Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Caligan Partners’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.
| Holder | Form | Date | Stake |
|---|---|---|---|
| Kynam Capital Management, LP | Schedule 13G | Feb 17, 2026 | 1.5% |
| Deep Track Capital, LP | Schedule 13G | May 8, 2026 | 5.3% |
| Bellevue Group AG | Schedule 13G | May 15, 2026 | 6.6% |
| Paradigm BioCapital Advisors LP | Schedule 13G | Jun 26, 2026 | 5.1% |
| State Street Corporation | Schedule 13G | Aug 7, 2026 | 5.5% |
| T. Rowe Price Associates, Inc. | Schedule 13G | Aug 14, 2026 | 5.2% |
| Point72 Asset Management, L.P. | Schedule 13G | Aug 20, 2026 | 5.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | Schedule 13G | Feb 17, 2026 | 11.8% |
| Vestal Point Capital, LP | Schedule 13G | May 15, 2026 | 5.5% |
| FMR LLC | Schedule 13G | Aug 6, 2026 | 8.8% |
| Wellington Management Group LLP | Schedule 13G | Aug 13, 2026 | 11.6% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Nantahala Capital | 13F | Nov 13, 2026 | 1.4% |
| Ra Capital Management, L.P. | 13F | Nov 16, 2026 | 5.5% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| FMR LLC | Schedule 13G | Sep 8, 2025 | 10.1% |
| T. Rowe Price Investment Management, Inc. | Schedule 13G | Nov 14, 2025 | 6.4% |
| Janus Henderson Group PLC | Schedule 13G | Nov 14, 2025 | 10.1% |
| Vanguard Capital Management | Schedule 13G | Apr 30, 2026 | 5.0% |
| RA Capital Management, L.P. | Schedule 13G | May 15, 2026 | 8.9% |
| JANUS HENDERSON GROUP Ltd. | Schedule 13G | Aug 7, 2026 | 0.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Raymond Debbane | Schedule 13G | Sep 22, 2025 | 5.3% |
| Farallon Partners, L.L.C. | Schedule 13G | Nov 12, 2025 | 9.3% |
| Adage Capital Management, L.P. | Schedule 13G | Nov 13, 2025 | 2.3% |
| TCG Crossover GP II, LLC | Schedule 13G | Nov 14, 2025 | 6.3% |
| BlackRock, Inc. | Schedule 13G | Jan 21, 2026 | 6.3% |
| The Vanguard Group | Schedule 13G | Jan 30, 2026 | 5.0% |
| Woodline Partners LP | Schedule 13G | Feb 17, 2026 | 7.5% |
| TCG Crossover GP II, L.P. | Schedule 13G | Feb 17, 2026 | 10.0% |
| FMR LLC | Schedule 13G | May 6, 2026 | 6.9% |
| RTW Investments, LP | Schedule 13G | May 15, 2026 | 9.3% |
| Nextech Crossover I GP S.a. r.l. | Schedule 13G | May 15, 2026 | 5.1% |
| The Goldman Sachs Group, Inc. | Schedule 13G | Aug 14, 2026 | 6.0% |
| Farallon Capital Management, L.L.C. | Schedule 13G | Aug 14, 2026 | 9.8% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| ForGrowth III PA B.V. | Schedule 13D | Dec 23, 2025 | 10.0% |
| Nantahala Capital | 13F | Aug 14, 2026 | 1.5% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Cannell Capital | 13F | May 15, 2026 | 4.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Viking Global Investors LP | Schedule 13D | Oct 16, 2023 | 9.5% |